Actively Recruiting
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Led by Alasht Pharmed · Updated on 2025-07-30
30
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks. The primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache). Secondary objectives included evaluating additional efficacy and safety outcomes of Canvert-M in managing migraine attacks.
CONDITIONS
Official Title
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 18 to 55 years
- Migraine diagnosis according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year
- Onset of migraine before age 50
- History of 2 to 8 migraine attacks per month
- Stable use of any migraine preventive medication for at least 2 months before screening and during the study
- Women of childbearing potential must use effective contraception during the study
- Ability to provide written informed consent and comply with study procedures
You will not qualify if you...
- Diagnosis of other primary (cluster or tension) or secondary headache disorders
- History of chronic migraine headaches
- History of resistant or refractory migraine headaches
- Use of any abortive migraine medication within 48 hours before using Canvert-M
- History of psychiatric or neurological disorders other than migraine, or medical conditions interfering with study results
- Allergy or sensitivity to menthol, lavender, rosemary, eucalyptus, wintergreen, or basil oil
- Presence of skin lesions where Canvert-M would be applied
- Treatment with any investigational drug within 30 days before screening
- History of substance use disorders
- Nursing mothers, pregnant women, or women planning pregnancy during the study
- Use of certain medications (e.g., carbamazepine, citalopram, warfarin) within 14 days before study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tehran Province, Tehran, Imam Khomeini Street (RA) - Before Hassan Abad Square
Tehran, Iran
Actively Recruiting
Research Team
H
Hamidreza Kafi Hamidreza Kafi,PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here